Idorsia gibt Finanzergebnisse für das erste Halbjahr 2021 bekannt – Entwicklung zum vollständig integrierten biopharmazeutischen Unternehmen schreitet dynamisch voran
July 27, 2021 01:01 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, Schweiz – 27. Juli 2021Idorsia Ltd (SIX: IDIA) veröffentlichte heute die Finanzergebnisse für das erste Halbjahr 2021. Operative Highlights ...
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
June 28, 2021 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland – June 28, 2021Idorsia Ltd (SIX: IDIA)...
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
June 28, 2021 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland – June 28, 2021Idorsia Ltd (SIX: IDIA)...
Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
June 09, 2021 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 9, 2021 Idorsia Ltd (SIX: IDIA) today announced that nine abstracts for daridorexant, the company’s investigational dual orexin receptor antagonist for the treatment of...
Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
June 09, 2021 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 9, 2021 Idorsia Ltd (SIX: IDIA) today announced that nine abstracts for daridorexant, the company’s investigational dual orexin receptor antagonist for the treatment of...
European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
May 25, 2021 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 25, 2021Idorsia Ltd (SIX: IDIA) was informed by the Janssen Pharmaceutical Companies of Johnson & Johnson that the European Commission (EC) has approved...
European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
May 25, 2021 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 25, 2021Idorsia Ltd (SIX: IDIA) was informed by the Janssen Pharmaceutical Companies of Johnson & Johnson that the European Commission (EC) has approved...
Idorsia hält ordentliche Generalversammlung ab
May 12, 2021 12:09 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Schweiz – 12. Mai 2021 Alle Anträge des Verwaltungsrates angenommen An der heute in Allschwil, Schweiz, abgehaltenen Generalversammlung von Idorsia Ltd (SIX: IDIA) stimmten die Aktionäre...
Idorsia holds its Annual General Meeting of Shareholders
May 12, 2021 12:09 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 12, 2021 All Board proposals approved by the Shareholders At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Allschwil, Switzerland, shareholders...
Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway
April 22, 2021 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – April 22, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2021. Business highlights Daridorexant new drug application (NDA)...